Molecular complexity of diffuse large B-cell lymphoma: Can it be a roadmap for precision medicine?

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma; it features extreme molecular heterogeneity regardless of the classical cell-of-origin (COO) classification. Despite this, the standard therapeutic approach is still immunochemotherapy (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone—R-CHOP), which allows a 60% overall survival (OS) rate, but up to 40% of patients experience relapse or refractory (R/R) disease. With the purpose of searching for new clinical parameters and biomarkers helping to make a better DLBCL patient characterization and stratification, in the last years a series of large discovery genomic and transcriptomic studies has been conducted, generating a wealth of information that needs to be put in order. We reviewed these researches, trying ultimately to understand if there are bases offering a roadmap toward personalized and precision medicine also for DLBCL

PET waste as organic linker source for the sustainable preparation of MOF-derived methane dry reforming catalysts

A catalyst made of Ni0 nanoparticles highly dispersed on a lamellar alumina support was prepared by an environmentally-friendly route. The latter involved the synthesis of an aluminum-containing metalorganic framework (MOF) MIL-53(Al) in which the linkers were derived from the depolymerization of polyethylene terephthalate (PET) originating from plastic wastes. After demonstrating the purity and structure integrity of the PET-derived MIL-53(Al), this MOF was impregnated with nickel nitrate salt and then calcined to form a lamellar Ni-Al2O3 mixed metal oxide with a high surface area (SBET = 1276 m2 g-1, N2 sorption). This mixed oxide consisted of nickel aluminate nanodomains dispersed within amorphous alumina, as revealed by PXRD and TPR analyses. Subsequent reduction under H2 resulted in the formation of well-dispersed 5 nm Ni0 nanoparticles homogeneously occluded within the interlamellar porosity of the γ-alumina matrix, as attested by electron microscopy. This waste-derived catalyst displayed catalytic performances in the reaction of dry reforming of methane (DRM) as good as its counterpart made from a MOF obtained from commercial benzene-1,4-dicarboxylic acid (BDC). Thus, under similar steady state conditions, at 650 °C and 1 bar, the PET-derived catalyst led to CH4 and CO2 conversions as high as those on the BDC-derived catalyst, and its catalytic stability and selectivity towards DRM were excellent as well (no loss of activity after 13 h and H2:CO products ratio remaining at 1). Moreover, both catalysts were much better than those of a reference nickel alumina catalyst prepared by conventional impregnation route. This work therefore demonstrates the possibility of using plastic wastes instead of commercial chemicals to prepare efficient porous nickel-alumina DRM catalysts from MOFs, fostering the concept of circular economy

Genomic segmental duplications on the basis of the t(9;22) rearrangement in chronic myeloid leukemia

n/

ADAMTS2 gene dysregulation in T/myeloid mixed phenotype acute leukemia.

Background: Mixed phenotype acute leukemias (MPAL) include acute leukemias with blasts that express antigens of more than one lineage, with no clear evidence of myeloid or lymphoid lineage differentiation. T/myeloid (T/My) MPAL not otherwise specified (NOS) is a rare leukemia that expresses both T and myeloid antigens, accounting for less than 1% of all leukemias but 89% of T/My MPAL. From a molecular point of view, very limited data are available on T/My MPAL NOS. Case presentation: In this report we describe a T/My MPAL NOS case with a complex rearrangement involving chromosomes 5 and 14, resulting in overexpression of the ADAM metallopeptidase with thrombospondin type 1 motif, 2 (ADAMTS2) gene due to its juxtaposition to the T cell receptor delta (TRD) gene segment. Conclusion: Detailed molecular cytogenetic characterization of the complex rearrangement in the reported T/My MPAL case allowed us to observe ADAMTS2 gene overexpression, identifying a molecular marker that may be useful for monitoring minimal residual disease. To our knowledge, this is the first evidence of gene dysregulation due to a chromosomal rearrangement in T/My MPAL NOS. Keywords: Mixed phenotype acute leukemia, ADAMTS2, TRD, Complex chromosomal rearrangement, Promoter swapping, Gene dysregulatio

Absolute quantification of the pretreatment PML-RARA transcript defines the relapse risk in acute promyelocytic leukemia.

In this study we performed absolute quantification of the PML-RARA transcript by droplet digital polymerase chain reaction (ddPCR) in 76 newly diagnosed acute promyelocytic leukemia (APL) cases to verify the prognostic impact of the PML-RARA initial molecular burden. ddPCR analysis revealed that the amount of PML-RARA transcript at diagnosis in the group of patients who relapsed was higher than in that with continuous complete remission (CCR) (272 vs 89.2 PML-RARA copies/ng, p = 0.0004, respectively). Receiver operating characteristic analysis detected the optimal PML-RARA concentration threshold as 209.6 PML-RARA/ng (AUC 0.78; p < 0.0001) for discriminating between outcomes (CCR versus relapse). Among the 67 APL cases who achieved complete remission after the induction treatment, those with > 209.6 PML-RARA/ng had a worse relapse-free survival (p = 0.0006). At 5-year follow-up, patients with > 209.6 PML-RARA/ng had a cumulative incidence of relapse of 50.3% whereas 7.5% of the patients with suffered a relapse (p < 0.0001). Multivariate analysis identified the amount of PML-RARA before induction treatment as the sole independent prognostic factor for APL relapse. Our results show that the pretreatment PML-RARA molecular burden could therefore be used to improve risk stratification in order to develop more individualized treatment regimens for high-risk APL cases

IRF4 expression is low in Philadelphia negative myeloproliferative neoplasms and is associated with a worse prognosis

Interferon regulatory factor 4 (IRF4) is involved in the pathogenesis of various hematologic malignancies. Its expression has been related to the negative regulation of myeloid-derived suppressor cells (MDSCs) and the polarization of anti-inflammatory M2 macrophages, thereby altering immunosurveillance and inflammatory mechanisms. An abnormal inflammatory status in the bone marrow microenvironment of myeloproliferative neoplasms (MPNs) has recently been demonstrated; moreover, in chronic myeloid leukemia a downregulated expression of IRF4 has been found. In this context, we evaluated the IRF4 expression in 119 newly diagnosed consecutive Philadelphia negative MPNs (Ph- MPNs), showing a low expression among the MPNs phenotypes with a more significant decrease in primary myelofibrosis patients. Lower IRF4 levels were associated with JAK2 + and triple negatives cases carrying the worst prognosis. Furthermore, the IRF4 levels were related to leukemic transformation and a shorter leukemia-free survival; moreover, the risk of myelofibrosis transformation in polycythemia vera and essential thrombocythemia patients was more frequent in cases with lower IRF4 levels. Overall, our study demonstrates an IRF4 dysregulated expression in MPNs patients and its association with a worse prognosis. Further studies could validate these data, to improve our knowledge of the MPNs pathogenesis and confirm the IRF4 role as a new prognostic factor

Autosomal Recessive Atrial Dilated Cardiomyopathy With Standstill Evolution Associated With Mutation of Natriuretic Peptide Precursor A

n/

Building a transnational biodiversity geo-database of the protected areas in the Adriatic-Ionian Macro-Region: approaches and results from the IMPRECO Project

Background The main objective of the project Common strategies and best practices to IMprove the transnational PRotection of ECOsystem integrity and services - IMPRECO is to enhance the safeguarding of ecosystems and ecosystem services. Additionally, the aim of this project is to tackle their environmental vulnerability by strengthening the potential of the Protected Areas in biodiversity, ecosystems and ecosystem services conservation. This is expected to be addressed by maintaining it through their transnational networking located in the European Adriatic-Ionian Macro-Region. New information The aim of this research is: 1) to characterise the habitats and ecosystems involved in the coastal-marine protected areas considered; 2) to set a biodiversity baseline; 3) to understand what current ecosystems' conditions are; 4) to build up a transnational biomonitoring programme of target species and habitats and 5) to assess their response to pilot actions. To do so, a transnational inventory of species, habitats, ecosystems and ecosystem services was established, starting with the seven coastal-marine protected areas involved in the project. Data collection was carried out using different sources of information: scientific literature, officially available data from NATURA 2000 Standard Data Forms, checklists from local biomonitoring programmes, personal observations and citizen science, historical maps and data from new in-field analyses. Data were filled in the transnational biodiversity geo-databases according to the NATURA 2000 standards about habitat features, species protection level and species features. The presence of alien species (non-indigenous species, NIS) was also acknowledged and references about data collection were provided in the databases according to the Darwin Core standards